These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 9715839)

  • 21. Zidovudine pharmacokinetics in zidovudine-induced bone marrow toxicity.
    Barry M; Howe JL; Back DJ; Swart AM; Breckenridge AM; Weller IV; Beeching N; Nye F
    Br J Clin Pharmacol; 1994 Jan; 37(1):7-12. PubMed ID: 8148221
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phosphorylated zidovudine concentrations in mononuclear cells in pediatric patients with human immunodeficiency virus infections.
    Wintermeyer SM; Nahata MC; Brady MT; Sobol BJ; Venglarcik JS 3rd ; Baker RC; Hunkler JA; McOwen NM
    Pediatr AIDS HIV Infect; 1997 Apr; 8(2):120-6. PubMed ID: 11361778
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of zidovudine after rectal administration in human immunodeficiency virus-infected patients.
    Wintergerst U; Rolinski B; Bogner JR; Notheis G; Goebel FD; Roscher AA; Belohradsky BH
    Antimicrob Agents Chemother; 1997 May; 41(5):1143-5. PubMed ID: 9145885
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interactions of antineoplastic chemotherapy with zidovudine pharmacokinetics in patients with HIV-related neoplasms.
    Toffoli G; Errante D; Corona G; Vaccher E; Bertola A; Robieux I; Aita P; Sorio R; Tirelli U; Boiocchi M
    Chemotherapy; 1999; 45(6):418-28. PubMed ID: 10567772
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oral zidovudine during labor to prevent perinatal HIV transmission, Bangkok: tolerance and zidovudine concentration in cord blood. Bangkok Collaborative Perinatal HIV Transmission Study Group.
    Bhadrakom C; Simonds RJ; Mei JV; Asavapiriyanont S; Sangtaweesin V; Vanprapar N; Moore KH; Young NL; Hannon WH; Mastro TD; Shaffer N
    AIDS; 2000 Mar; 14(5):509-16. PubMed ID: 10780713
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in patients with the acquired immunodeficiency syndrome.
    Barry M; Howe JL; Ormesher S; Back DJ; Breckenridge AM; Bergin C; Mulcahy F; Beeching N; Nye F
    Br J Clin Pharmacol; 1994 May; 37(5):421-6. PubMed ID: 8054247
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nonclinical toxicology studies with zidovudine: genetic toxicity tests and carcinogenicity bioassays in mice and rats.
    Ayers KM; Clive D; Tucker WE; Hajian G; de Miranda P
    Fundam Appl Toxicol; 1996 Aug; 32(2):148-58. PubMed ID: 8921318
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of oral ganciclovir alone and in combination with zidovudine, didanosine, and probenecid in HIV-infected subjects.
    Cimoch PJ; Lavelle J; Pollard R; Griffy KG; Wong R; Tarnowski TL; Casserella S; Jung D
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Mar; 17(3):227-34. PubMed ID: 9495222
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nevirapine significantly reduces the levels of racemic methadone and (R)-methadone in human immunodeficiency virus-infected patients.
    Stocker H; Kruse G; Kreckel P; Herzmann C; Arastéh K; Claus J; Jessen H; Cordes C; Hintsche B; Schlote F; Schneider L; Kurowski M
    Antimicrob Agents Chemother; 2004 Nov; 48(11):4148-53. PubMed ID: 15504834
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Maternal and fetal zidovudine pharmacokinetics during pregnancy and labour: too high dose infused at labour?
    Fauchet F; Treluyer JM; Valade E; Benaboud S; Pannier E; Firtion G; Foissac F; Bouazza N; Urien S; Hirt D
    Br J Clin Pharmacol; 2014 Dec; 78(6):1387-96. PubMed ID: 25040510
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II, randomized, open-label, community-based trial to compare the safety and activity of combination therapy with recombinant interferon-alpha2b and zidovudine versus zidovudine alone in patients with asymptomatic to mildly symptomatic HIV infection. HIV Protocol C91-253 Study Team.
    Krown SE; Aeppli D; Balfour HH
    J Acquir Immune Defic Syndr Hum Retrovirol; 1999 Mar; 20(3):245-54. PubMed ID: 10077172
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of steady-state pharmacokinetic interactions between ritonavir-boosted BILR 355, a non-nucleoside reverse transcriptase inhibitor, and lamivudine/zidovudine in healthy subjects.
    Huang F; Allen L; Huang DB; Moy F; Vinisko R; Nguyen T; Rowland L; MacGregor TR; Castles MA; Robinson P
    J Clin Pharm Ther; 2012 Feb; 37(1):81-8. PubMed ID: 21128991
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multidose pharmacokinetics of ritonavir and zidovudine in human immunodeficiency virus-infected patients.
    Cato A; Qian J; Hsu A; Levy B; Leonard J; Granneman R
    Antimicrob Agents Chemother; 1998 Jul; 42(7):1788-93. PubMed ID: 9661022
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics of zidovudine in end-stage renal disease: influence of haemodialysis.
    Pachon J; Cisneros JM; Castillo JR; Garcia-Pesquera F; Cañas E; Viciana P
    AIDS; 1992 Aug; 6(8):827-30. PubMed ID: 1418779
    [TBL] [Abstract][Full Text] [Related]  

  • 35. AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients.
    AIDS; 2000 Mar; 14(4):367-74. PubMed ID: 10770538
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative pharmacokinetics of zidovudine and its toxic catabolite 3'-amino-3'-deoxythymidine in HIV-infected patients.
    Zhou XJ; Sommadossi JP
    AIDS Res Hum Retroviruses; 1996 Feb; 12(3):229-33. PubMed ID: 8835201
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High exposure to zidovudine during the first 2 weeks of life and concentration-toxicity relationships.
    Hirt D; Warszawski J; Firtion G; Giraud C; Chappuy H; Lechenadec J; Benaboud S; Urien S; Blanche S; Tréluyer JM
    J Acquir Immune Defic Syndr; 2013 Aug; 63(5):555-62. PubMed ID: 23481669
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Population pharmacokinetics study of recommended zidovudine doses in HIV-1-infected children.
    Fauchet F; Treluyer JM; Frange P; Urien S; Foissac F; Bouazza N; Benaboud S; Blanche S; Hirt D
    Antimicrob Agents Chemother; 2013 Oct; 57(10):4801-8. PubMed ID: 23877688
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of HIV triple therapy on methadone levels.
    Akerele EO; Levin F; Nunes E; Brady R; Kleber H
    Am J Addict; 2002; 11(4):308-14. PubMed ID: 12584873
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.
    Siegfried N; van der Merwe L; Brocklehurst P; Sint TT
    Cochrane Database Syst Rev; 2011 Jul; (7):CD003510. PubMed ID: 21735394
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.